{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:08:03Z","timestamp":1778630883918,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["A81\/2008"],"award-info":[{"award-number":["A81\/2008"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["A154\/2010"],"award-info":[{"award-number":["A154\/2010"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.urology.2019.12.006","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:47:22Z","timestamp":1577144842000},"page":"84-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of CYP2D6 Polymorphisms on Tamoxifen Treatment in Patients With Retroperitoneal Fibrosis: A First Step Towards Tailored Therapy?"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2153-7371","authenticated-orcid":false,"given":"Nici Markus","family":"Dreger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Degener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Ahmad-Nejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kamper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich Carl","family":"von Rundstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Sascha","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2019.12.006_bib0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2019.12.006_bib0002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s00120-016-0081-x","article-title":"[Diagnosis and treatment of retroperitoneal fibrosis]","volume":"55","author":"Brandt","year":"2016","journal-title":"Der Urologe Ausg A"},{"key":"10.1016\/j.urology.2019.12.006_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MD.0b013e3181afc420","article-title":"Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation","volume":"88","author":"van Bommel","year":"2009","journal-title":"Medicine"},{"key":"10.1016\/j.urology.2019.12.006_bib0004","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00120-017-0428-y","article-title":"[New (and old) aspects of retroperitoneal fibrosis]","volume":"56","author":"Brandt","year":"2017","journal-title":"Der Urologe Ausg A"},{"key":"10.1016\/j.urology.2019.12.006_bib0005","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1097-0142(19831215)52:12<2201::AID-CNCR2820521204>3.0.CO;2-#","article-title":"Remission of rapidly growing desmoid tumors after tamoxifen therapy","volume":"52","author":"Kinzbrunner","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2019.12.006_bib0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2011010046","article-title":"Antifibrotic effect of tamoxifen in a model of progressive renal disease","volume":"23","author":"Delle","year":"2012","journal-title":"J Am Soc Nephrol: JASN"},{"key":"10.1016\/j.urology.2019.12.006_bib0007","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000322255","article-title":"Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis","volume":"31","author":"Huang","year":"2011","journal-title":"Blood purif"},{"key":"10.1016\/j.urology.2019.12.006_bib0008","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejim.2012.11.010","article-title":"Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis","volume":"24","author":"van Bommel","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.urology.2019.12.006_bib0009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000357814","article-title":"Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis","volume":"93","author":"Brandt","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2019.12.006_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2019.12.006_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ckj\/sfv148","article-title":"Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy","volume":"9","author":"van der Bilt","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.urology.2019.12.006_bib0012","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7150\/ijms.5708","article-title":"Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer","volume":"10","author":"Zafra-Ceres","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.urology.2019.12.006_bib0013","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.urology.2019.12.006_bib0014","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2019.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","article-title":"Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2019.12.006_bib0016","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.juro.2010.09.105","article-title":"Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry","volume":"185","author":"Brandt","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.12.006_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1012552211996","article-title":"Do SF-36 summary component scores accurately summarize subscale scores?","volume":"10","author":"Taft","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.urology.2019.12.006_bib0018","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)64677-0","article-title":"Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration","volume":"168","author":"Kardar","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.12.006_bib0019","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2009.04.019","article-title":"Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment","volume":"54","author":"Swartz","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.urology.2019.12.006_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00120-014-3712-0","article-title":"Therapy of retroperitoneal fibrosis: Functional therapeutic outcome","volume":"54","author":"Brandt","year":"2015","journal-title":"Der Urologe. Ausg. A"},{"key":"10.1016\/j.urology.2019.12.006_bib0021","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10067-010-1580-6","article-title":"Idiopathic retroperitoneal fibrosis (RPF): clinical features of 61 cases and literature review","volume":"30","author":"Li","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.urology.2019.12.006_bib0022","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.2004.029793","article-title":"Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature","volume":"64","author":"Warnatz","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.urology.2019.12.006_bib0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-410X.2006.06210.x","article-title":"Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment","volume":"98","author":"Ilie","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2019.12.006_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-154-1-201101040-00005","article-title":"Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series","volume":"154","author":"Scheel","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urology.2019.12.006_bib0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.juro.2007.03.057","article-title":"Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis","volume":"178","author":"Scheel","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.12.006_bib0026","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2007.02.268","article-title":"Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone","volume":"49","author":"van Bommel","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.urology.2019.12.006_bib0027","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.urology.2019.12.006_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.DMPK-11-RV-084","article-title":"Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters","volume":"27","author":"Kiyotani","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.urology.2019.12.006_bib0029","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","article-title":"The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2019.12.006_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-beta: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519311057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519311057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:09:58Z","timestamp":1778627398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429519311057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"alternative-id":["S0090429519311057"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2019.12.006","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of CYP2D6 Polymorphisms on Tamoxifen Treatment in Patients With Retroperitoneal Fibrosis: A First Step Towards Tailored Therapy?","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}